Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.93 USD
Change Today +0.64 / 6.22%
Volume 419.9K
TROV On Other Exchanges
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

trovagene inc (TROV) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/11/15 - $11.68
52 Week Low
08/1/14 - $2.97
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TROVAGENE INC (TROV)

trovagene inc (TROV) Related Bloomberg News

View More Bloomberg News

trovagene inc (TROV) Related Businessweek News

No Related Businessweek News Found

trovagene inc (TROV) Details

Trovagene, Inc., a molecular diagnostic company, focuses on the development and commercialization of proprietary urine-based cell-free molecular diagnostic technology for use in disease detection and monitoring across various medical disciplines. The company intends to enhance the treatment outcomes for cancer patients through its proprietary technology to detect and quantitatively monitor cell-free DNA using urine or blood samples. It is developing PCM BRAF and KRAS mutation detection tests for detecting mutations in metastatic cancer patients; and HPV HR detection test to detect the presence of various HPV genotypes using a urine sample. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

31 Employees
Last Reported Date: 03/12/15
Founded in 1999

trovagene inc (TROV) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $539.0K
Chief Financial Officer
Total Annual Compensation: $338.8K
Chief Scientific Officer
Total Annual Compensation: $430.0K
Compensation as of Fiscal Year 2014.

trovagene inc (TROV) Key Developments

TrovaGene, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

TrovaGene, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues of $0.127 million compared to $0.111 million a year ago. Operating loss was $4.848 million compared to $3.260 million a year ago. Net loss and comprehensive loss was $7.174 million compared to $3.190 million a year ago. Net loss and comprehensive loss attributable to common stockholders was $7.180 million or $0.33 per basic and diluted share compared to $3.199 million or $0.17 per basic and diluted share a year ago. The increase in net loss is primarily due to increased operating expenses and a loss on the change in the fair value of certain derivative instruments warrants during the first quarter of 2015 as compared to the prior year comparable period.

Trovagene, Inc. Announces Encouraging Data from Metastatic Lung Cancer Study

Trovagene, Inc. announced data from a clinical study which demonstrated that its urine-based Precision Cancer Monitoring, or PCM, platform showed sensitivity compared to tissue biopsy for the detection and monitoring of EGFR T790M mutations in metastatic lung cancer patients. In an interim analysis of 34 patients from an ongoing clinical study, the company's PCM platform detected the T790M mutation in all patients who were positive for the mutation in tissue biopsy. The Company's urine-based assay identified additional patients as T790M-positive, including those who had clinical suspicion of T790M-progressive disease, but were either negative by tissue biopsy or had not yet undergone tissue biopsy for confirmation. The company's PCM platform detected EGFR T790M resistance mutations months earlier than radiologic detection of progression in patients. Early pharmacodynamic events occurring within hours or days of anti-EGFR drug treatment were evaluated in the study by implementing daily monitoring of urinary ctDNA. Initial results demonstrated that immediate changes in EGFR mutational load using a urine specimen may identify patients who respond to anti-EGFR therapy much earlier than with follow-up CT-scans. "These interim results suggest that use of urinary ctDNA has potential to detect EGFR T790M status in a higher number of study subjects and may make some patients eligible for therapy who would by tissue biopsy be falsely classified as negative," stated Hatim Husain, M.D., University of California, San Diego Moores Cancer Center.

TrovaGene, Inc., Q1 2015 Earnings Call, May 05, 2015

TrovaGene, Inc., Q1 2015 Earnings Call, May 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TROV:US $10.93 USD +0.64

TROV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fluidigm Corp $24.71 USD -0.52
Genomic Health Inc $27.24 USD +0.13
Laboratory Corp of America Holdings $121.42 USD +1.06
Veracyte Inc $10.69 USD -0.15
View Industry Companies

Industry Analysis


Industry Average

Valuation TROV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 805.1x
Price/Book 11.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 703.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TROVAGENE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at